Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study
The prophylactic use of PEG-rhG-CSF in patients with advanced NSCLC undergoing first-line immunochemotherapy did not compromise efficacy and safety. It reduced chemotherapy interruptions and neutropenia, without increasing immune-related adverse events, thus supporting safe and uninterrupted treatment.
Authors
- Jietao Ma (ORCID: https://orcid.org/0000-0002-0979-7488)
- Le‐Tian Huang (ORCID: https://orcid.org/0000-0002-1889-743X)
- Li Sun (ORCID: https://orcid.org/0000-0002-4991-655X)
- Shuling Zhang (ORCID: https://orcid.org/0000-0003-2002-8628)
- Cheng‐Bo Han (ORCID: https://orcid.org/0000-0001-8391-6134)
- Yuan Tian (ORCID: https://orcid.org/0000-0001-8158-1588)
Institutions
- China Medical University (CN)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100780
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Shengjing Hospital